ReviewPharmacognosy reviews2014
Cytotoxicity of dietary flavonoids on different human cancer types.
Review in Pharmacognosy reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 160 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
160 citing papers in PubMed, 1 synthesis or guideline pooled it, 452 citations in OpenAlex.
- Dietary intake of flavonoid subclasses and risk of colorectal cancer: evidence from population studies.Oncotarget · 2016Pooled it
- Novel Diterpenoids From Salvia rosmarinus Reveal a Compound With Antiproliferative and Antioxidant Activities.Archiv der Pharmazie · 2026Article
- Naringenin Attenuates Methotrexate-Induced Nephrotoxicity Accompanied by Alterations in Oxidative Stress, Inflammatory, Apoptotic, and Endoplasmic Reticulum Stress Responses.International journal of molecular sciences · 2026Article
- XBP1 gene silencing augments quercetin-induced apoptosis and anti-metastatic activity in breast cancer cell lines.3 Biotech · 2026Article
- Flavonoids and semi-synthetic derivatives targeting oncogenic inflammation: dose-response relationships, toxicological profiles, and synergistic potential.Inflammopharmacology · 2026Review
- Interaction of flavonoids with DNA: implications in cancer treatment.Molecular biology reports · 2026Review
- Regio- and chemoselective synthesis of flavanone isosteres via multicomponent reactions: synergistic role of hydrogen bonding and solvent effects.Molecular diversity · 2026Article
- Anticancer Activity and Cell Mechanism of a Novel Flavonoid Derivative fromCancer management and research · 2026Article
- Therapeutic role of naringin in cancer: molecular pathways, synergy with other agents, and nanocarrier innovations.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Role of Human DNA Ligases in Mediating Pharmacological Activities of Flavonoids.International journal of molecular sciences · 2025Article
- MicroRNAs at the crossroad of cancer therapeutics: insights from WNT signaling & flavonoids.Frontiers in molecular biosciences · 2025Review
- Cytotoxic Natural Products fromInternational journal of molecular sciences · 2024Article
- Cytotoxicity, Proapoptotic Activity and Drug-like Potential of Quercetin and Kaempferol in Glioblastoma Cells: Preclinical Insights.International journal of molecular sciences · 2024Article
- Metabolomic Profiling ofACS omega · 2024Article
- Article
- Antimicrobial and cytotoxic activities of flavonoid and phenolics extracted from Sepia pharaonis ink (Mollusca: Cephalopoda).BMC biotechnology · 2024Article
- Review
- The Pros and Cons of Estrogens in Prostate Cancer: An Update with a Focus on Phytoestrogens.Biomedicines · 2024Review
- Study of the anti-cancer activity of a mesoporous silica nanoparticle surface coated with polydopamine loaded with umbelliprenin.Scientific reports · 2024Article
- Targeting colorectal cancer using dietary flavonols.Cancer innovation · 2024Review
100 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flavonoids are ubiquitous in nature. They are also in food, providing an essential link between diet and prevention of chronic diseases including cancer. Anticancer effects of these polyphenols depend on several factors: Their chemical structure and concentration, and also on the type of cancer. Malignant cells from different tissues reveal somewhat different sensitivity toward flavonoids and, therefore, the preferences of the most common dietary flavonoids to various human cancer types are analyzed in this review. While luteolin and kaempferol can be considered as promising candidate agents for treatment of gastric and ovarian cancers, respectively, apigenin, chrysin, and luteolin have good perspectives as potent antitumor agents for cervical cancer; cells from main sites of flavonoid metabolism (colon and liver) reveal rather large fluctuations in anticancer activity probably due to exposure to various metabolites with different activities. Anticancer effect of flavonoids toward blood cancer cells depend on their myeloid, lymphoid, or erythroid origin; cytotoxic effects of flavonoids on breast and prostate cancer cells are highly related to the expression of hormone receptors. Different flavonoids are often preferentially present in certain food items, and knowledge about the malignant tissue-specific anticancer effects of flavonoids could be purposely applied both in chemoprevention as well as in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.